Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Bioepis's Etanercept Biosimilar To Be Rolled Out In Europe

This article was originally published in Scrip

Executive Summary

Samsung Bioepis Co. Ltd. has received a marketing approval from the European Commission for its biosimilar version of Amgen Inc.'s Enbrel (etanercept), the first etanercept biosimilar to be approved by the Commission and therefore likely the first to debut in Europe. But Sandoz is close behind – the Swiss company's biosimilar etanercept was accepted by review by European regulators in December 2015.

Advertisement

Related Content

Samsung Looks Beyond Biosimilars Via Takeda Tie-Up
Samsung Seeks Third Anti-TNF Biosimilar Launch In Europe
Biogen Adds To Biosimilar Anti-TNF Portfolio In Europe With Flixabi

Topics

Advertisement
UsernamePublicRestriction

Register

SC064251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel